Emerging Therapies Spark Interest in Rare Cardiovascular Disease

The global market for pulmonary arterial hypertension (PAH) treatments is expected to reach nearly $11 billion by 2030, attracting the interest of biopharma companies. PAH is a rare cardiovascular disease characterized by the thickening and narrowing of arteries in the lungs, leading to fatal heart failure. Current treatments focus on symptom relief but do not address the underlying cause of the disease. However, new therapies like sotatercept, which targets cell proliferation, show promise in reversing the disease. Anti-proliferation drugs are driving a "new wave" of PAH treatments, and their development could also benefit related diseases like pulmonary hypertension secondary to heart failure.